NRDL initiates Phase I trial of metabolic drug

The company had submitted the clinical trial application for P1201-07 to the Central Committee on Research Involving Human Subjects (CCMO), the regulatory authority of the Netherlands, and the Independent Ethics Committee of the foundation Evaluation Of Ethics in Biomedical Research (BEBO), Assen, Netherlands. Both these bodies have approved the company’s application to initiate the Phase I study of P1201-07

Swati Piramal, director of Strategic Alliances & Communications, NPIL, said: “This is our fourth new drug to enter the clinic and the first from the research collaboration with pharma major Eli Lilly. The drug development timeline is on schedule.”